Jianmin Group (600976): Performance is in line with expectations, sports training, Niu Huang's performance is outstanding

Key investment events: Jianmin Group released its 2024 quarterly report. During the reporting period, it achieved revenue of 970 million yuan (-4.27% year over year), net profit to mother of 100 million yuan (-0.04% year over year), net profit of zero non-return to mother

浙商證券Apr 20 00:00

Jianmin Group (600976.SH) announced first-quarter results, net profit of 99.52 million yuan, a year-on-year decrease of 0.04%

Jianmin Group (600976.SH) disclosed its report for the first quarter of 2024. The company achieved 9.7 revenue during the reporting period...

Zhitong FinanceApr 19 17:44

Jianmin Group (600976.SH) will distribute 1.2 yuan per share in 2023. The stock registration date is April 25

Jianmin Group (600976.SH) issued an announcement that the company will implement the 2023 annual equity distribution, distributed per share...

Zhitong FinanceApr 19 17:42

Jianmin Group (600976.SH): The phase II clinical trial of the company's product Tongzheng Granule is in the summary stage

Gelonghui April 16 丨 Some investors asked Jianmin Group (600976.SH) through an interactive platform: How is your company's clinical progress in Tongzheng Granule? How long until launch? Jianmin Group (600976.SH) replied: The second phase clinical trial of the company's product Tongzheng Granule is in the summary stage. There is some uncertainty in the development of new drugs. Investors are kindly requested to pay attention to investment risks.

Gelonghui FinanceApr 16 17:53

Jianmin Pharma Gets Nod to Market Asthma Drug

Jianmin Pharmaceutical Group (SHA:600976) obtained approval from China's National Medical Products Administration to market its terbutaline sulfate atomized inhalation product, the company said in a T

MT NewswiresApr 16 14:40

Express News | Jianmin Group: Terbutaline sulfate nebulized inhalation solution approved for listing

BreakingsApr 15 18:39